Adusumalli, V.E., Choi, Y.M., Romanyshyn, L.A., Sparadoski, R.E.Jr., Wichmann, J.K., Wong, K.K., Kucharczyk, N. and Sofia, R.D. (1993): Isolation and identification of 3-carbamoyloxy-2- phenylpropionic acid as a major human urinary metabolite of felbamate. Drug Metab. Dispos., 21, 710-716.
Dalvie, D., Obach, R.S., Kang, P., Prakash, C., Loi, C.M., Hurst, S., Nedderman, A., Goulet, L., Smith, E., Bu, H.Z. and Smith, D.A. (2009): Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem. Res. Toxicol., 22, 357-368.
De Serres, M., Bowers, G., Boyle, G., Beaumont, C., Castellino, S., Sigafoos, J., Dave, M., Roberts, A., Shah, V., Olson, K., Patel, D., Wagner, D., Yeager, R. and Serabjit-Singh, C. (2011): Evaluation of a chimeric (uPA+/+)/SCID mouse model with a humanized liver for prediction of human metabolism. Xenobiotica, 41, 464-475.
Di, L. (2019): The impact of carboxylesterases in drug metabolism and pharmacokinetics. Curr. Drug Metab., 20, 91-102.
Dieckhaus, C.M., Miller, T.A., Sofia, R.D. and Macdonald T.L. (2000): A mechanistic approach to understanding species differences in felbamate bioactivation: relevance to drug-induced idiosyncratic reactions. Drug Metab. Dispos., 28, 814-822.
Dieckhaus, C.M., Santos, W.L., Sofia, R.D. and Macdonald T.L. (2001): The chemistry, toxicology, and identification in rat and human urine of 4-hydroxy-5-phenyl-1,3-oxazaperhydroin-2-one: a reactive metabolite in felbamate bioactivation. Chem. Res. Toxicol., 14, 958-964.
Dieckhaus, C.M., Thompson, C.D., Roller, S.G. and Macdonald, T.L. (2002): Mechanisms of idiosyncratic drug reactions: the case of felbamate. Chem. Biol. Interact., 142, 99-117.
European Medicines Agency (2009): ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m3r2-non-clinical- safety-studies-conduct-human-clinical-trials-marketing-authorisation_en.pdf
Food and Drug Administration (2008): Safety Testing of Drug Metabolites. -Guidance for Industry- https://www.fda.gov/media/72279/download
Glue, P., Banfield, C.R., Perhach, J.L., Mather, G.G., Racha, J.K. and Levy, R.H. (1997): Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation. Clin. Pharmacokinet., 33, 214-224.
Goldstein, J.A. (2001): Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol., 52, 349-355.
Goto, T., Terada, N., Inoue, T., Nakayama, K., Okada, Y., Yoshikawa, T., Miyazaki, Y., Uegaki, M., Sumiyoshi, S., Kobayashi, T., Kamba, T., Yoshimura, K. and Ogawa, O. (2014): The expression profile of phosphatidylinositol in high spatial resolution imaging mass spectrometry as a potential biomarker for prostate cancer. PLoS One, 9, e90242.
Hosokawa, M. (2008): Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules, 13, 412-431.
Inoue, T., Sugihara, K., Ohshita, H., Horie, T., Kitamura, S. and Ohta, S. (2009): Prediction of human disposition toward S-3H-warfarin using chimeric mice with humanized liver. Drug Metab. Pharmacokinet., 24, 153-160.
Ikeda, T. (2015): Recent findings regarding the mechanism of idiosyncratic drug toxicity. YAKUGAKU ZASSHI, 135, 567-578
Kakuni, M., Morita, M., Matsuo, K., Katoh, Y., Nakajima, M., Tateno, C. and Yokoi, T. (2012): Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury. Toxicol. Lett., 214, 9-18.
Kamimura, H., Nakada, N., Suzuki, K., Mera, A., Souda, K., Murakami, Y., Tanaka, K., Iwatsubo, T., Kawamura, A. and Usui, T. (2010): Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. Drug Metab. Pharmacokinet., 25, 223-235.
Kapetanovic, I.M., Torchin, C.D., Strong, J.M., Yonekawa, W.D., Lu, C., Li, A.P., Dieckhaus, C.M., Santos, W.L., Macdonald, T.L., Sofia, R.D. and Kupferberg, H.J. (2002): Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro. Chem. Biol. Interact., 142, 119-134.
Kassahun, K., Pearson, P.G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G. and Baillie, T.A. (2001): Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol., 14, 62-70
Katoh, M., Matsui, T., Nakajima, M., Tateno, C., Kataoka, M., Soeno, Y., Horie, T., Iwasaki, K., Yoshizato, K. and Yokoi, T. (2004): Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab. Dispos., 32, 1402-1410.
Katoh, M., Matsui, T., Okumura, H., Nakajima, M., Nishimura, M., Naito, S., Tateno, C., Yoshizato, K. and Yokoi, T. (2005): Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab. Dispos., 33, 1333-1340.
Katoh, M. and Yokoi, T. (2007): Application of chimeric mice with humanized liver for predictive ADME. Drug Metab. Rev., 39, 145-157.
Kaufman, D.W., Kelly, J.P., Anderson, T., Harmon, D.C. and Shapiro, S. (1997): Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia, 38, 1265-1269.
Kawashima, M., Iwamoto, N., Kawaguchi-Sakita, N., Sugimoto, M., Ueno, T., Mikami, Y., Terasawa, K., Sato, T.A., Tanaka, K., Shimizu, K. and Toi, M. (2013): High-resolution imaging mass spectrometry reveals detailed spatial distribution of phosphatidylinositols in human breast cancer. Cancer Sci., 104, 1372-1379.
Kitamura, S., Nitta, K., Tayama, Y., Tanoue, C., Sugihara, K., Inoue, T., Horie, T. and Ohta, S. (2008): Aldehyde oxidase-catalyzed metabolism of N1-methylnicotinamide in vivo and in vitro in chimeric mice with humanized liver. Drug Metab. Dispos., 36, 1202-1205.
Kola, I. and Landis, J. (2004): Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov., 3, 711-715
Martignoni, M., Groothuis, G.M. and de Kanter, R. (2006): Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol., 2, 875-894.
McGee, J.H., Erikson, D.J., Galbreath, C., Willigan, D.A. and Sofia, R.D. (1998): Acute, subchronic, and chronic toxicity studies with felbamate, 2-phenyl-1,3-propanediol dicarbamate. Toxicol. Sci., 45, 225-232.
Nakayama, S., Atsumi, R., Takakusa, H., Kobayashi, Y., Kurihara, A., Nagai, Y., Nakai, D. and Okazaki O. (2009): A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab. Dispos., 37, 1970-1997.
Nishidate, M., Hayashi, M., Aikawa, H., Tanaka, K., Nakada, N., Miura, S.I., Ryu, S., Higashi, T., Ikarashi, Y., Fujiwara, Y. and Hamada, A. (2019): Applications of MALDI mass spectrometry imaging for pharmacokinetic studies during drug development. Drug Metab. Pharmacokinet., 34, 209-216.
Nishimura, M., Yoshitsugu, H., Yokoi, T., Tateno, C., Kataoka, M., Horie, T., Yoshizato, K. and Naito, S. (2005): Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver. Xenobiotica, 35, 877-890.
Ohtsuki, S., Kawakami, H., Inoue, T., Nakamura, K., Tateno, C., Katsukura, Y., Obuchi, W., Uchida, Y., Kamiie, J., Horie, T. and Terasaki, T. (2014): Validation of uPA/SCID mouse with humanized liver as a human liver model: protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases by LC-MS/MS. Drug Metab. Dispos., 42, 1039-1043.
Park, B.K., Kitteringham, N.R., Maggs, J.L., Pirmohamed, M. and Williams, D.P. (2005): The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol., 45, 177-202
Park, B.K., Pirmohamed, M. and Kitteringham, N.R. (1998): Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem. Res. Toxicol., 11, 969-988.
Sanoh, S., Yamachika, Y., Tamura, Y., Kotake, Y., Yoshizane, Y., Ishida, Y., Tateno, C. and Ohta, S. (2017): Assessment of amiodarone-induced phospholipidosis in chimeric mice with a humanized liver. J. Toxicol. Sci., 42, 589-596.
Satoh, H., Gillette, J.R., Davies, H.W., Schulick, R.D. and Pohl, L.R. (1985): Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats. Mol. Pharmacol., 28, 468-474.
Shimma, S., Sugiura, Y., Hayasaka, T., Hoshikawa, Y., Noda, T. and Setou, M. (2007): MALDI-based imaging mass spectrometry revealed abnormal distribution of phospholipids in colon cancer liver metastasis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 855, 98-103.
Smith, M.T. (2003): Mechanisms of troglitazone hepatotoxicity. Chem. Res. Toxicol., 16, 679-687.
Sugiura, Y. and Setou, M. (2010): Imaging mass spectrometry for visualization of drug and endogenous metabolite distribution: toward in situ pharmacometabolomes. J. Neuroimmune Pharmacol., 5, 31-43.
Sun, N., Fernandez, I.E., Wei, M., Wu, Y., Aichler, M., Eickelberg, O. and Walch, A. (2016): Pharmacokinetic and pharmacometabolomic study of pirfenidone in normal mouse tissues using high mass resolution MALDI-FTICR-mass spectrometry imaging. Histochem. Cell Biol., 145, 201-211.
Takai, N. and Tanaka, Y. (2015): Imaging of drug and metabolite distribution by MS: case studies. Bioanalysis, 7, 2639-2648.
Taketani, M., Shii, M., Ohura, K., Ninomiya, S. and Imai, T. (2007): Carboxylesterase in the liver and small intestine of experimental animals and human. Life Sci., 81, 924-932.
Tateno, C., Kawase, Y., Tobita, Y., Hamamura, S., Ohshita, H., Yokomichi, H., Sanada, H., Kakuni, M., Shiota, A., Kojima, Y., Ishida, Y., Shitara, H., Wada, N.A., Tateishi, H., Sudoh, M., Nagatsuka, S., Jishage, K. and Kohara, M. (2015): Generation of novel chimeric mice with humanized livers by using hemizygous cDNA-uPA/SCID mice. PLoS One, 10, e0142145.
Tettey, J.N., Maggs, J.L., Rapeport, W.G., Pirmohamed, M. and, B.K. (2001): Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem. Res. Toxicol., 14, 965-974.
Thompson, C.D., Kinter, M.T. and Macdonald, T.L. (1996): Synthesis and in vitro reactivity of 3- carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal: Putative reactive metabolites of felbamate. Chem. Res. Toxicol., 9, 1225-1229.
United States Prescribing Information: felbatol https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Walgren, J.L., Mitchell, M.D. and Thompson, D.C. (2005): Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol., 35, :325-361
Yamazaki, H., Kuribayashi, S., Inoue, T., Tateno, C., Nishikura, Y., Oofusa, K., Harada, D., Naito, S., Horie, T. and Ohta, S. (2010): Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5-a] pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry. Chem. Res. Toxicol., 23, 152-158.
Yang, J.T., Adusumalli, V.E., Wong, K.K., Kucharczyk, N. and Sofia, R.D. (1991): Felbamate metabolism in the rat, rabbit, and dog. Drug Metab. Dispos., 19, 1126-1134.
山田久陽,山口順一,飯田泉,奥山茂(2006)：特異体質性薬物毒性.日薬理誌,127，473-480．
論文の公開元へ
